These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 35769681)

  • 1. Unraveling the Mysteries of Mental Illness With Psilocybin.
    Sotille R; Singh H; Weisman A; Vida T
    Cureus; 2022 May; 14(5):e25414. PubMed ID: 35769681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sub-acute effects of psilocybin on EEG correlates of neural plasticity in major depression: Relationship to symptoms.
    Skosnik PD; Sloshower J; Safi-Aghdam H; Pathania S; Syed S; Pittman B; D'Souza DC
    J Psychopharmacol; 2023 Jul; 37(7):687-697. PubMed ID: 37392016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing potential of psilocybin for depressive disorders.
    Kozak Z; Johnson MW; Aaronson ST
    Expert Opin Investig Drugs; 2023; 32(10):887-900. PubMed ID: 37869790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential Therapeutic Effects of Psilocybin: A Systematic Review.
    Goel DB; Zilate S
    Cureus; 2022 Oct; 14(10):e30214. PubMed ID: 36381758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of Psilocybin-Assisted Therapy in Medicine: A Narrative Review.
    Ziff S; Stern B; Lewis G; Majeed M; Gorantla VR
    Cureus; 2022 Feb; 14(2):e21944. PubMed ID: 35273885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Psilocybin-assisted psychotherapy for depression: Emerging research on a psychedelic compound with a rich history.
    Pearson C; Siegel J; Gold JA
    J Neurol Sci; 2022 Mar; 434():120096. PubMed ID: 34942586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular Mechanisms of Psilocybin and Implications for the Treatment of Depression.
    Ling S; Ceban F; Lui LMW; Lee Y; Teopiz KM; Rodrigues NB; Lipsitz O; Gill H; Subramaniapillai M; Mansur RB; Lin K; Ho R; Rosenblat JD; Castle D; McIntyre RS
    CNS Drugs; 2022 Jan; 36(1):17-30. PubMed ID: 34791625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current Understanding on Psilocybin for Major Depressive Disorder: A Review Focusing on Clinical Trials.
    Wang SM; Kim S; Choi WS; Lim HK; Woo YS; Pae CU; Bahk WM
    Clin Psychopharmacol Neurosci; 2024 May; 22(2):222-231. PubMed ID: 38627070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DARK Classics in Chemical Neuroscience: Psilocybin.
    Geiger HA; Wurst MG; Daniels RN
    ACS Chem Neurosci; 2018 Oct; 9(10):2438-2447. PubMed ID: 29956917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels.
    Madsen MK; Fisher PM; Burmester D; Dyssegaard A; Stenbæk DS; Kristiansen S; Johansen SS; Lehel S; Linnet K; Svarer C; Erritzoe D; Ozenne B; Knudsen GM
    Neuropsychopharmacology; 2019 Jun; 44(7):1328-1334. PubMed ID: 30685771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Psilocybin-induced changes in brain network integrity and segregation correlate with plasma psilocin level and psychedelic experience.
    Madsen MK; Stenbæk DS; Arvidsson A; Armand S; Marstrand-Joergensen MR; Johansen SS; Linnet K; Ozenne B; Knudsen GM; Fisher PM
    Eur Neuropsychopharmacol; 2021 Sep; 50():121-132. PubMed ID: 34246868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The emerging role of psilocybin and MDMA in the treatment of mental illness.
    Gill H; Gill B; Chen-Li D; El-Halabi S; Rodrigues NB; Cha DS; Lipsitz O; Lee Y; Rosenblat JD; Majeed A; Mansur RB; Nasri F; Ho R; McIntyre RS
    Expert Rev Neurother; 2020 Dec; 20(12):1263-1273. PubMed ID: 32954860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Efficacy of psychedelics in psychiatry, a systematic review of the literature].
    Berkovitch L; Roméo B; Karila L; Gaillard R; Benyamina A
    Encephale; 2021 Aug; 47(4):376-387. PubMed ID: 33888297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Therapeutic Potential of Psilocybin.
    Lowe H; Toyang N; Steele B; Valentine H; Grant J; Ali A; Ngwa W; Gordon L
    Molecules; 2021 May; 26(10):. PubMed ID: 34063505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hallucinogenic/psychedelic 5HT2A receptor agonists as rapid antidepressant therapeutics: Evidence and mechanisms of action.
    Dos Santos RG; Hallak JE; Baker G; Dursun S
    J Psychopharmacol; 2021 Apr; 35(4):453-458. PubMed ID: 33740877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Psilocybin for Treating Psychiatric Disorders: A Psychonaut Legend or a Promising Therapeutic Perspective?
    Coppola M; Bevione F; Mondola R
    J Xenobiot; 2022 Feb; 12(1):41-52. PubMed ID: 35225956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Return of the psychedelics: Psilocybin for treatment resistant depression.
    Patra S
    Asian J Psychiatr; 2016 Dec; 24():51-52. PubMed ID: 27931907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Self-administration of Psilocybin in the Setting of Treatment-resistant Depression.
    Lyons A
    Innov Clin Neurosci; 2022; 19(7-9):44-47. PubMed ID: 36204170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance.
    Dinis-Oliveira RJ
    Drug Metab Rev; 2017 Feb; 49(1):84-91. PubMed ID: 28074670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future.
    Carhart-Harris RL; Goodwin GM
    Neuropsychopharmacology; 2017 Oct; 42(11):2105-2113. PubMed ID: 28443617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.